Skip to content

Adverse Effects of Systemic Hypoglycemia Exposure on Endothelial Function in Humans

Adverse Effects of Systemic Hypoglycemia Exposure on Endothelial Function in Humans

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01660009
Enrollment
5
Registered
2012-08-08
Start date
2012-06-30
Completion date
2017-06-30
Last updated
2017-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Keywords

Endothelial Function, Hypoglycemia, Mitochondria

Brief summary

Prior work suggests exposure to low glucose levels (hypoglycemia) is associated with increased cardiovascular risk. However, whether there is a causal relationship between cardiovascular events and hypoglycemia remains unclear with conflicting data in the literature. In this study, we plan to study whether acute exposure of patients to clinically relevant (50-60 milligrams/deciliter) levels of hypoglycemia induces or worsens blood vessel endothelial dysfunction- a key 1st step in the development of heart attacks and strokes. This will be determined in humans both with and with type 2 diabetes.

Interventions

OTHERGlycemic clamping

During hypoglycemic clamping, individuals will have a blood glucose level of 50-60 mg/dL for approximately 1 hour prior to outcome measurements. During euglycemic clamping, individuals will have a blood glucose level of 85-99 mg/dL for approximately 1 hour prior to outcome measurements.

Sponsors

Medical College of Wisconsin
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

\- Type 2 Diabetes Inclusion Criteria 1. Adult age 21 or older 2. If on 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase reductase therapy, must be on a stable dose for at least 6 weeks prior to enrollment 3. Diagnosis of type 2 diabetes by a physician as defined by the American Diabetes Association standard criteria: 1) Fasting Plasma glucose at or above 126 mg/dL 2) a two-hour value in an oral glucose tolerance test at or above 200 mg/dL, or 3) a random plasma glucose concentration 200 mg/dL in the presence of symptoms, or 4) glycosylated hemoglobin greater than or equal to 6.5%. Score of \< 4 using the Gold method for assessing hypoglycemia awareness Inclusion Criteria for Healthy subjects 1. Adult age 21 or older 2. No evidence of metabolic syndrome or diabetes, hypertension (BP≥140/90), or high cholesterol (LDL≥160) at the time of screen.

Exclusion criteria

1. History of stroke, peripheral arterial disease, or coronary artery disease (as defined by the presence of at least one coronary stenosis ≥ 40% on angiography or by confirmed history of myocardial infarction by standard criteria) 2. Evidence of other evident major illness including chronic renal insufficiency(plasma creatinine \> 1.4 for women or 1.5 for men), liver disease (aspartate aminotransferase or alanine aminotransferase greater than 2.5 x normal), and cancer currently undergoing therapy or had therapy for cancer within 1 year of enrollment. 3. Pregnancy as determine by urinary pregnancy test 4. Subjects on warfarin, oral anti-thrombin inhibitors, or thienopyridines 5. Subjects who have had changes to dosing of thiazolidinedione, dipeptidyl peptidase-4 (DPP-4) inhibitor, or metformin therapy within 6 weeks of enrollment. 6. Failed Allen's test in both arms - unable to safely place an arterial line 7. Glucose reading of \< 50 mg/dL and/or episodes of symptomatic hypoglycemia requiring the assistance of another person for recovery in the 2 years prior to enrollment. 8. History of hypoglycemic convulsions 9. Current fluoxetine therapy (known to interfere with neuroendocrine response to hypoglycemia) 10. Glycosylated hemoglobin over 8.5% 11. On aldosterone antagonist therapy at the time of enrollment 12. On insulin therapy at the time of screening. 13. History of allergy to local anesthetic injection like lidocaine. 14. Age below 21.

Design outcomes

Primary

MeasureTime frame
Flow induced Dilation of the Brachial Artery (FMD%)1 hour

Secondary

MeasureTime frameDescription
Measurement of total and phosphorylated endothelium-derived NO synthase expression in radial artery endothelial cells.1 hour
Measurement of mitochondrial membrane potential1 hourPerformed on captured radial artery endothelial cells.
Mitochondrial superoxide production1 hourFrom capture radial artery endothelial cells.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026